Vanguard Group Inc Intellia Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,190,053 shares of NTLA stock, worth $125 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,190,053
Previous 9,627,804
5.84%
Holding current value
$125 Million
Previous $198 Million
39.95%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
96.1MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$154 Million1.28% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$118 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$63.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$46.8 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.99MShares$36.7 Million0.02% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $933M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...